CANY
KZR

Caxton Associates (New York)’s Kezar Life Sciences KZR Stock Holding History

Caxton Associates (New York)’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,177
Closed -$197K – 616
2021
Q4 		$197K Buy
+1,177
New +$133K 0.02% 495

Other funds holding KZR

BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Caxton Associates (New York)'s KZR Position: Q1 2022 in Review

Caxton Associates (New York) sold out of Kezar Life Sciences (KZR) in Q1 2022, closing a stake of 1,177 shares — an estimated $197K sold.

Caxton Associates (New York) first reported a position in KZR in Q4 2021 and held it in 1 quarter. The position peaked at $197K in Q4 2021. 123 funds tracked by Wall St. Rank hold KZR as of Q1 2022.

  • Caxton Associates (New York) reported no remaining Kezar Life Sciences position as of Q1 2022 after selling out during the quarter.
  • Caxton Associates (New York) sold 1,177 Kezar Life Sciences shares in Q1 2022, an estimated $197K.
  • Caxton Associates (New York) first reported a position in Kezar Life Sciences in Q4 2021 and held it in 1 quarter.
  • Caxton Associates (New York)'s Kezar Life Sciences position peaked at $197K in Q4 2021.
  • 123 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q1 2022.

Based on Caxton Associates (New York)'s 13F filing for Q1 2022, filed 16 May 2022.